Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15093554 | 1.00 | CYP3A4 (0.71) | CYP3A4PSIP1NR1I2KDM4EALDH1A1 | |
| SCHEMBL16657166 | 0.94 | CYP3A4 (0.62) | CYP3A4PSIP1 | |
| SCHEMBL1699622 | 0.94 | CYP3A4 (0.71) | CYP3A4PSIP1NR1I2MAPK14 | |
| SCHEMBL15093285 | 0.94 | CYP3A4 (0.71) | CYP3A4PSIP1NR1I2MAPK14 | |
| SCHEMBL15093284 | 0.94 | CYP3A4 (0.71) | CYP3A4PSIP1NR1I2MAPK14 | |
| SCHEMBL16657200 | 0.94 | CYP3A4 (0.62) | CYP3A4PSIP1 | |
| SCHEMBL15153827 | 0.92 | CYP3A4 (0.69) | CYP3A4PSIP1NR1I2 | |
| SCHEMBL1699752 | 0.92 | CYP3A4 (0.69) | CYP3A4PSIP1NR1I2 | |
| SCHEMBL15153872 | 0.92 | CYP3A4 (0.69) | CYP3A4PSIP1NR1I2MAPK14 | |
| SCHEMBL10271799 | 0.92 | CYP3A4 (0.69) | CYP3A4PSIP1NR1I2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150111891-A1 | NAPHTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | GILEAD SCIENCES, INC. (US) | 2015-04-23 | — | — | US | disclosed |
| WO-2013103738-A1 | NAPTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | GILEAD SCIENCES, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111891-A1 | NAPHTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | NFATC1, ACIN1, NAAA | CYP3A4 1722/4885PSIP1 3735/4885NR1I2 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.